Merck will obtain the exclusive global license for Chinese pharmaceutical company Hansu's HS-10535, an investigational oral drug that targets the GLP-1 receptor. Read more
Merck will obtain the exclusive global license for Chinese pharmaceutical company Hansu's HS-10535, an investigational oral drug that targets the GLP-1 receptor. Read more